Aripiprazole (VS PharmTech)

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameAripiprazole (VS PharmTech)
Drug Alias NameVS-101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRadiosensitizersSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor agonists +[10] 
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptorDopamine D4 receptor +[9] 
Therapy Area/IndicationsPancreatic NeoplasmsBreast NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVS PharmTech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesVS PharmTech Co Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsBreast NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A